Background Molecular characterization of breast cancer allows subtype-directed
interventions. Estrogen receptor (ER) is the longest-established molecular marker. Methods …

Importance Given recent advances in screening mammography and adjuvant therapy
(treatment), quantifying their separate and combined effects on US breast cancer mortality …

Purpose Since 1990, overall breast cancer mortality rates in the United States decreased
24%. This decline has been attributed to mammography screening and adjuvant systemic …

Background. Researchers question whether estrogen receptorα-negative (ERN) and-
positive (ERP) represent different stages of one disease or different breast cancer types …

Background: Risk factors may differentially influence development of estrogen receptor (ER)–
positive vs–negative breast cancer. We examined associations with strong, prevalent risk …

Importance Breast cancer mortality in the US declined between 1975 and 2019. The
association of changes in metastatic breast cancer treatment with improved breast cancer …

While debate continues regarding short-term changes in breast cancer incidence and the
impact of screening on mortality, a long-term view of trends in incidence and mortality may …

Background. Breast cancer is a heterogeneous and chronic disease with relapses and
death occurring 25 years or more after primary diagnosis. Standard tumor characteristics are …

Purpose Breast cancer mortality began declining in many Western countries during the late
1980s. We estimated the proportion of improvements in stage-and age-specific breast …

Improvement in breast cancer survival has been observed in recent decades in the US, but it
is unclear if similar survival gains are consistent across breast cancer subtypes, especially …